Skip to main content
SpringerLink
Log in

Alkylating Agents

  • Chapter
  • First Online:
Treatment of Non-infectious Uveitis

Abstract

The alkylating agents cyclophosphamide and chlorambucil have been utilized in medicine for over 50 years. As our knowledge about the pharmacokinetics of these agents has grown, treatment regimens have evolved. While alkylating agents have been shown to be highly effective in the treatment of ocular inflammation, their use has been limited by the risks of serious side effects including sterility and malignancy. They remain an important tool in the arsenal of treatments, however, particularly in the case of sight-threatening disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gilman A, Philips FS. The biological actions and therapeutic applications of the B-chloroethyl amines and sulfides. Science. 1946;103(2675):409–15.

    Article  CAS  PubMed  Google Scholar 

  2. Goodman LS, Brunton LL, Chabner B, Knollmann BC. Goodman & Gilman’s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill; 2011. xvi, 2084 p.

    Google Scholar 

  3. Roda E. Uveitis treated with nitrogen mustard. Am J Ophthalmol. 1952;35(1):114.

    Article  CAS  PubMed  Google Scholar 

  4. Lacki JK, Schochat T, Sobieska M, Leszczynski P, Wiktorowicz K, Mackiewicz U, et al. Immunological studies in patients with rheumatoid arthritis treated with methotrexate or cyclophosphamide. Z Rheumatol. 1994;53(2):76–82.

    CAS  PubMed  Google Scholar 

  5. Fauci AS, Wolff SM, Johnson JS. Effect of cyclophosphamide upon the immune response in Wegener’s granulomatosis. N Engl J Med. 1971;285(27):1493–6.

    Article  CAS  PubMed  Google Scholar 

  6. Bagley CM Jr, Bostick FW, DeVita VT Jr. Clinical pharmacology of cyclophosphamide. Cancer Res. 1973;33(2):226–33.

    PubMed  Google Scholar 

  7. Katzung BG, Trevor AJ. Basic & clinical pharmacology. New York: McGraw-Hill Education LLC; 2015. Available from: http://hdl.library.upenn.edu/1017.12/1492976 Connect to full text.

  8. Dinant HJ, Decker JL, Klippel JH, Balow JE, Plotz PH, Steinberg AD. Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis. Ann Intern Med. 1982;96(6 Pt 1):728–36.

    Article  CAS  PubMed  Google Scholar 

  9. Eiser AR, Grishman E, Dreznin S. Intravenous pulse cyclophosphamide in the treatment of type IV lupus nephritis. Clin Nephrol. 1993;40(3):155–9.

    CAS  PubMed  Google Scholar 

  10. Jampol LM, West C, Goldberg MF. Therapy of scleritis with cytotoxic agents. Am J Ophthalmol. 1978;86(2):266–71.

    Article  CAS  PubMed  Google Scholar 

  11. Jabs DA, Mudun A, Dunn JP, Marsh MJ. Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol. 2000;130(4):469–76.

    Article  CAS  PubMed  Google Scholar 

  12. Pujari SS, Kempen JH, Newcomb CW, Gangaputra S, Daniel E, Suhler EB, et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology. 2010;117(2):356–65.

    Article  PubMed  Google Scholar 

  13. Durrani K, Papaliodis GN, Foster CS. Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety. Ophthalmology. 2004;111(5):960–5.

    Article  PubMed  Google Scholar 

  14. Khan IJ, Barry RJ, Amissah-Arthur KN, Carruthers D, Elamanchi SR, Situnayake D, et al. Ten-year experience of pulsed intravenous cyclophosphamide and methylprednisolone protocol (PICM protocol) in severe ocular inflammatory disease. Br J Ophthalmol. 2013;97(9):1118–22.

    Article  PubMed  Google Scholar 

  15. Akpek EK, Jabs DA, Tessler HH, Joondeph BC, Foster CS. Successful treatment of serpiginous choroiditis with alkylating agents. Ophthalmology. 2002;109(8):1506–13.

    Article  PubMed  Google Scholar 

  16. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116(6):488–98.

    Article  CAS  PubMed  Google Scholar 

  17. Blumenfeld Z, Avivi I, Linn S, Epelbaum R, Ben-Shahar M, Haim N. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod. 1996;11(8):1620–6.

    Article  CAS  PubMed  Google Scholar 

  18. Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus. 2000;9(6):401–5.

    Article  CAS  PubMed  Google Scholar 

  19. Koyama H, Wada T, Nishizawa Y, Iwanaga T, Aoki Y. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer. 1977;39(4):1403–9.

    Article  CAS  PubMed  Google Scholar 

  20. Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum. 1998;41(5):831–7.

    Article  CAS  PubMed  Google Scholar 

  21. Meistrich ML, Wilson G, Brown BW, da Cunha MF, Lipshultz LI. Impact of cyclophosphamide on long-term reduction in sperm count in men treated with combination chemotherapy for Ewing and soft tissue sarcomas. Cancer. 1992;70(11):2703–12.

    Article  CAS  PubMed  Google Scholar 

  22. Martin F, Lauwerys B, Lefebvre C, Devogelaer JP, Houssiau FA. Side-effects of intravenous cyclophosphamide pulse therapy. Lupus. 1997;6(3):254–7.

    Article  CAS  PubMed  Google Scholar 

  23. Radis CD, Kahl LE, Baker GL, Wasko MC, Cash JM, Gallatin A, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum. 1995;38(8):1120–7.

    Article  CAS  PubMed  Google Scholar 

  24. Kirshon B, Wasserstrum N, Willis R, Herman GE, McCabe ER. Teratogenic effects of first-trimester cyclophosphamide therapy. Obstet Gynecol. 1988;72(3 Pt 2):462–4.

    CAS  PubMed  Google Scholar 

  25. Gebhardt DO. The embryo lethal and teratogenic effects of cyclophosphamide on mouse embryos. Teratology. 1970;3(3):273–7.

    Article  CAS  PubMed  Google Scholar 

  26. McLean A, Newell D, Baker G, Connors T. The metabolism of chlorambucil. Biochem Pharmacol. 1980;29(14):2039–47.

    Article  CAS  PubMed  Google Scholar 

  27. Palmer RG, Dore CJ, Denman AM. Chlorambucil-induced chromosome damage to human lymphocytes is dose-dependent and cumulative. Lancet. 1984;1(8371):246–9.

    Article  CAS  PubMed  Google Scholar 

  28. Tessler HH, Jennings T. High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behcet’s disease. Br J Ophthalmol. 1990;74(6):353–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Goldstein DA, Fontanilla FA, Kaul S, Sahin O, Tessler HH. Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology. 2002;109(2):370–7.

    Article  PubMed  Google Scholar 

  30. Patel SS, Dodds EM, Echandi LV, Couto CA, Schlaen A, Tessler HH, et al. Long-term, drug-free remission of sympathetic ophthalmia with high-dose, short-term chlorambucil therapy. Ophthalmology. 2014;121(2):596–602.

    Article  PubMed  Google Scholar 

  31. Mamo JG, Azzam SA. Treatment of Behcet’s disease with chlorambucil. Arch Ophthalmol. 1970;84(4):446–50.

    Article  CAS  PubMed  Google Scholar 

  32. Abdalla MI, el DBN. Long-lasting remission of Behcet’s disease after chlorambucil therapy. Br J Ophthalmol. 1973;57(9):706–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Godfrey WA, Epstein WV, O’Connor GR, Kimura SJ, Hogan MJ, Nozik RA. The use of chlorambucil in intractable idiopathic uveitis. Am J Ophthalmol. 1974;78(3):415–28.

    Article  CAS  PubMed  Google Scholar 

  34. Elliott JH, Ballinger WH. Behcet’s syndrome: treatment with chlorambucil. Trans Am Ophthalmol Soc. 1984;82:264–81.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Miserocchi E, Baltatzis S, Ekong A, Roque M, Foster CS. Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience. Ophthalmology. 2002;109(1):137–42.

    Article  PubMed  Google Scholar 

  36. Mudun BA, Ergen A, Ipcioglu SU, Burumcek EY, Durlu Y, Arslan MO. Short-term chlorambucil for refractory uveitis in Behcet’s disease. Ocul Immunol Inflamm. 2001;9(4):219–29.

    Article  CAS  PubMed  Google Scholar 

  37. O’Duffy JD, Robertson DM, Goldstein NP. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behcet’s disease. Am J Med. 1984;76(1):75–84.

    Article  PubMed  Google Scholar 

  38. Guesry P, Lenoir G, Broyer M. Gonadal effects of chlorambucil given to prepubertal and pubertal boys for nephrotic syndrome. J Pediatr. 1978;92(2):299–303.

    Article  CAS  PubMed  Google Scholar 

  39. Reeves BR, Casey G, Harris H, Dinning WJ. Long-term cytogenetic follow-up study of patients with uveitis treated with chlorambucil. Carcinogenesis. 1985;6(11):1615–9.

    Article  CAS  PubMed  Google Scholar 

  40. Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol. 2002;20(18):3878–84.

    Article  PubMed  Google Scholar 

  41. Birnbaum AD, Oh F, Sahin O, Little DM, Tessler HH, Goldstein DA. Chlorambucil and malignancy. Ophthalmology. 2010;117(7):1466–e1.

    Article  PubMed  Google Scholar 

  42. Shotton D, Monie IW. Possible teratogenic effect of chlorambucil on a human fetus. JAMA. 1963;186:74–5.

    Article  CAS  PubMed  Google Scholar 

  43. Salder TW, Kochhar DM. Teratogenic effects of chlorambucil on in vivo and in vitro organogenesis in mice. Teratology. 1975;12(1):71–8.

    Article  CAS  PubMed  Google Scholar 

  44. Murphy ML. A comparison of the teratogenic effects of five polyfunctional alkylating agents on the rat fetus. Pediatrics. 1959;23(1 Part 2):231–44.

    CAS  PubMed  Google Scholar 

  45. Diwo E, Gueudry J, Saadoun D, Weschler B, LeHoang P, Bodaghi B. Long-term efficacy of interferon in severe uveitis associated with Behcet disease. Ocul Immunol Inflamm. 2017;25(1):76–84.

    Article  PubMed  Google Scholar 

  46. Deuter C, Stubiger N, Zierhut M. Interferon-alpha therapy in noninfectious uveitis. Dev Ophthalmol. 2012;51:90–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    Debra A. Goldstein

  2. Department of Ophthalmology, Boston University School of Medicine, Boston, MA, USA

    Kara C. LaMattina

Authors
  1. Debra A. Goldstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kara C. LaMattina
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Oregon Health and Science University, Casey Eye Institute, Portland, OR, USA

    Phoebe Lin

  2. Oregon Health and Science University, OHSU-PSU School of Public Health, Portland Veterans Administration Medical Center, Portland, OR, USA

    Eric Suhler

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Goldstein, D.A., LaMattina, K.C. (2019). Alkylating Agents. In: Lin, P., Suhler, E. (eds) Treatment of Non-infectious Uveitis. Springer, Cham. https://doi.org/10.1007/978-3-030-22827-9_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-22827-9_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-22825-5

  • Online ISBN: 978-3-030-22827-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation